FindTrial
Sign In

Neutralizing antibody response and influencing factors in patients with hematological malignancies after breakthrough infection of SARS-CoV-2 Omicron variant: a multicenter, prospective, observational study

Neutralizing antibody level test in patients with hematological malignancies after breakthrough infection of SARS-CoV-2 Omicron variant: a multicenter, prospective, observational study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071830
Enrollment
Unknown
Registered
2023-05-25
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

HM patient group:None
Healthy control group:None
Solid tumor control group:None

Sponsors

Chongqing University Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.Inclusion criteria for HM group (1) Age ? 18 years old; (2) HM patients with SARS-CoV-2 infection (confirmed by RT-PCR or two consecutive positive antigen results plus typical COVID-19 symptoms); (3) HM patients from Chongqing, with SARS-Cov-2 infection in or out of hospital; (4) HM patients not at terminal stage, with expected survival time > 2 months; 2.Inclusion criteria for healthy control group (1) Age ? 18 years old; (2) SARS-CoV-2 infection confirmed by RT-PCR or two consecutive positive antigen results plus typical COVID-19 symptoms; (3) 3-6 weeks after SARS-CoV-2 infection; 3.Inclusion criteria for solid tumor control group (1) Age ? 18 years old; (2) Solid tumor participants with SARS-CoV-2 infection confirmed by RT-PCR or two consecutive positive antigen results plus typical COVID-19 symptoms; (3) 3-6 weeks after SARS-CoV-2 infection; (4) Solid tumor patients not at terminal stage, with expected survival time > 2 months.

Exclusion criteria

Exclusion criteria: 1.Exclusion criteria for HM group (1) Previous history of COVID-19; (2) Co-existing with solid tumors; (3) Patients with severe COVID-19 symptoms requiring mechanical ventilation or ICU treatment; 2.Exclusion criteria for healthy control group (1) Previous history of COVID-19; (2) History/condition of immunosuppression (such as diabetes, autoimmune disease, malignant tumor, congenital immune deficiency, immunosuppressive treatment, etc.); (3) Patients with severe COVID-19 symptoms requiring mechanical ventilation or ICU treatment; 3.Exclusion criteria for solid tumor control group (1) Previous history of COVID-19; (2) Co-existing with HM; (3) Patients with severe COVID-19 symptoms requiring mechanical ventilation or ICU treatment.

Design outcomes

Primary

MeasureTime frame
Neutralizing antibody titer;—

Countries

China

Contacts

Public ContactYao Liu

Chongqing University Cancer Hospital

liuyao77@cqu.edu.cn+86 132 2868 4685

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026